Background The European Society for Medical Oncology-Magnitude of Clinical Benefit
Scale (ESMO-MCBS) is a validated, widely used tool developed to score the clinical benefit …

Opportunities to decrease the toxicity and cost of approved treatment regimens with lower
dose, less frequent, or shorter duration alternative regimens have been limited by the …

Importance Although quality of life (QOL) is an important clinical end point, cancer drugs are
often approved based on overall survival (OS) or putative surrogate end points such as …

The cost of cancer drugs is a challenge to patients and healthcare systems. Here, we
propose a new paradigm of near-equivalence, which combines various types of evidence to …

PURPOSE Cancer care–related greenhouse gas (GHG) emissions harm human health.
Many cancer drugs are administered at greater-than-necessary doses, frequencies, and …

Objectives Shwachman-Diamond syndrome (SDS) is a rare autosomal recessive disorder.
Its predominant manifestations include exocrine pancreatic insufficiency, bone marrow …

Background Noninferiority (NI) and equivalence trials evaluate whether an experimental
therapy's effect on the primary endpoint (PEP) is contained within an acceptable margin …

Over the past decades, dose selection of anticancer drugs has been dictated by the
maximum tolerated dose (MTD), based on tolerability rather than efficacy. 1 Tolerability …

Objectives The purpose of this study was to conduct a methodological review of research on
the effects of conflicts of interest (COIs) in research contexts. Design Methodological review …

Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple Myeloma |
Hematology | JAMA Oncology | JAMA Network [Skip to Navigation] Our website uses …